Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Souvenaid in the management of mild cognitive impairment: an expert consensus opinion.

Cummings J, Passmore P, McGuinness B, Mok V, Chen C, Engelborghs S, Woodward M, Manzano S, Garcia-Ribas G, Cappa S, Bertolucci P, Chu LW.

Alzheimers Res Ther. 2019 Aug 17;11(1):73. doi: 10.1186/s13195-019-0528-6. Review.

2.

[«Apuntes en Neurologia» (Notes in Neurology): a synthesis of the evidence on common paroxysmal neurological disorders and on neurodegenerative disorders].

Toledo M, Carnero-Pardo C, Carreno-Martinez M, Escudero-Torrella J, Gaig C, Garcia-Ribas G, Gil-Nagel A, Grandas FJ, Kulisevsky J, Lainez-Andres JM, Pareja JA, Porta-Etessam J, Poza-Aldea JJ, Rodriguez-Oroz MC, Serratosa JM, Villanueva V.

Rev Neurol. 2018 Nov 26;67(s01):S1-S21. Review. Spanish.

PMID:
30484273
3.

Does normal substantia nigra echogenicity make a difference in Parkinson's disease diagnosis? A real clinical practice follow-up study.

Alonso-Canovas A, Lopez-Sendon Moreno JL, Buisan J, Sainz de la Maza S, Costa-Frossard L, Garcia-Ribas G, de Felipe-Mimbrera A, Matute-Lozano MC, Zarza Sanz B, Toledano Delgado R, Corral I, Masjuan J, Martinez-Castrillo JC.

J Neurol. 2018 Oct;265(10):2363-2369. doi: 10.1007/s00415-018-9006-5. Epub 2018 Aug 16.

PMID:
30116942
4.

[Cognitive impairment as a predictor of functional decline after hospitalization: DECOFIRH Study].

de Alboniga-Chindurza A, Anciones C, Acebron F, Ibanez D, Roiz-Rey P, Perez-Torre P, Garcia-Ribas G.

Rev Neurol. 2017 Nov 1;65(9):405-408. Spanish.

5.

CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration.

Alcolea D, Vilaplana E, Suárez-Calvet M, Illán-Gala I, Blesa R, Clarimón J, Lladó A, Sánchez-Valle R, Molinuevo JL, García-Ribas G, Compta Y, Martí MJ, Piñol-Ripoll G, Amer-Ferrer G, Noguera A, García-Martín A, Fortea J, Lleó A.

Neurology. 2017 Jul 11;89(2):178-188. doi: 10.1212/WNL.0000000000004088. Epub 2017 Jun 7.

PMID:
28592456
6.

Use of e-mail for Parkinson's disease consultations: Are answers just a clic away?

Viedma-Guiard E, Agüero P, Crespo-Araico L, Estévez-Fraga C, Sánchez-Díez G, López-Sendón JL, Aviles-Olmos I, García-Ribas G, Palacios Romero ML, Masjuan Vallejo J, Martínez-Castrillo JC, Alonso-Cánovas A.

Neurologia. 2018 Mar;33(2):107-111. doi: 10.1016/j.nrl.2016.05.020. Epub 2016 Jul 26. English, Spanish.

7.

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

López-Sendón Moreno JL, García Caldentey J, Trigo Cubillo P, Ruiz Romero C, García Ribas G, Alonso Arias MA, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutierrez S, García-Bermejo ML, Fernández Ruiz J, Guzmán M, García de Yébenes Prous J.

J Neurol. 2016 Jul;263(7):1390-400. doi: 10.1007/s00415-016-8145-9. Epub 2016 May 9.

PMID:
27159993
8.

PET biomarkers: Use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis.

García-Ribas G, Arbizu J, Carrió I, Garrastachu P, Martinez-Lage P.

Neurologia. 2017 Jun;32(5):275-277. doi: 10.1016/j.nrl.2016.03.002. Epub 2016 May 5. English, Spanish. No abstract available.

9.

Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment.

Canuet L, Pusil S, López ME, Bajo R, Pineda-Pardo JÁ, Cuesta P, Gálvez G, Gaztelu JM, Lourido D, García-Ribas G, Maestú F.

J Neurosci. 2015 Jul 15;35(28):10325-30. doi: 10.1523/JNEUROSCI.0704-15.2015.

10.

Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.

Arbizu J, García-Ribas G, Carrió I, Garrastachu P, Martínez-Lage P, Molinuevo JL.

Rev Esp Med Nucl Imagen Mol. 2015 Sep-Oct;34(5):303-13. doi: 10.1016/j.remn.2015.03.002. Epub 2015 Jun 20. English, Spanish.

PMID:
26099942
11.

[Biomarkers in Alzheimer's disease].

García-Ribas G, López-Sendón Moreno JL, García-Caldentey J.

Rev Neurol. 2014 Apr 1;58(7):308-17. Review. Spanish.

12.

[Multidimensional alcohol craving scale and [123I] iodobenzamide SPECT as predictors of early relapse in alcohol-dependent patients].

Guardia-Serecigni J, Estorch M, Surkov S, del Valle Camacho M, García-Ribas G.

Adicciones. 2011;23(2):157-64. Spanish.

13.

Risk factors for dementia of Alzheimer type and aging-associated cognitive decline in a Spanish population based sample, and in brains with pathology confirmed Alzheimer's disease.

Ampuero I, Ros R, Royuela A, Abraira V, del Ser T, García-Ribas G, García de Yébenes J.

J Alzheimers Dis. 2008 Jun;14(2):179-91.

PMID:
18560129
14.

[Determinants of prophylactic migraine therapy in Spain].

Pascual-Gómez J, Caminero AB, Cano A, Heras-Pérez JA, Leira-Muiño R, García-Ribas G; grupo de investigadores participantes en el estudio PREVENTIA.

Rev Neurol. 2007 Nov 1-15;45(9):513-8. Spanish.

15.

[Observational study on safety, tolerability and effectiveness of galantamine in patients with mild to moderately severe Alzheimer's disease].

Blesa R, García Ribas G, Galdós L, Olascoaga J, Amer G, Marey López J, Barquero M, Marsall C, Ezpeleta D.

Neurologia. 2006 Jul-Aug;21(6):289-96. Spanish.

PMID:
16799903
16.

Use of topiramate in treatment-resistant bipolar spectrum disorders.

Vieta E, Torrent C, Garcia-Ribas G, Gilabert A, Garcia-Parés G, Rodriguez A, Cadevall J, García-Castrillón J, Lusilla P, Arrufat F.

J Clin Psychopharmacol. 2002 Aug;22(4):431-5.

PMID:
12172346
17.

Tuberculous brain abscess should be considered in HIV/AIDS patients.

Velasco-Martínez JJ, Guerrero-Espejo A, Gómez-Mampaso E, Navas-Elorza E, García-Ribas G.

AIDS. 1995 Oct;9(10):1197-9. Review. No abstract available.

PMID:
8519460
18.

[Demyelinating polyradiculitis in neuro borreliosis].

Corral I, Sanchís G, García-Ribas G, Quereda C, Escudero R, de Blas G.

Neurologia. 1995 Feb;10(2):110-13. Spanish.

PMID:
7695939

Supplemental Content

Loading ...
Support Center